Article

OPKO Health acquires company

OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.

Miami-OPKO Health has acquired Vidus Ocular, a privately held company developing a shunt (Aquashunt) to treat glaucoma.

The patented device was designed by M. Bruce Shields, MD, chairman emeritus, Department of Ophthalmology and Visual Science, Yale University School of Medicine. Dr. Shields is chief scientific and medical officer at Vidus Ocular.

"Preclinical data on the device are encouraging, and we believe that OPKO is an ideal partner to assume responsibility for the development and commercialization of this potentially important product," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.